Sub 5c now on sell side. We go down on bad ASX days, and also down on good ASX days.... consistently. This is causing shareholders a lot of grief. I attribute 90% of the continued decline to the lack of any meaningful ( non-fluffy) comment from management on the current trials. Other biotechs sometimes provide "interim" data with the caveat that trials are not complete so a definitive outcome cannot be provided until trialling is complete. I'd settle for that for the time being.
Ann: 2021 Annual Report to Shareholders, page-119
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
